Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells

Eun Ji Kim, Gyeoung Jin Kang, Jung Il Kang, Hye Jin Boo, Jin Won Hyun, Young Sang Koh, Weon Young Chang, Young Ree Kim, Jung Mi Kwon, Young Hee Maeng, Eun Sook Yoo, Chang Hoon Lee, Hee Kyoung Kang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho- GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5- FU cells. These data suggest that inhibition of AKT activation may overcome 5-FUresistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment.

Original languageEnglish (US)
Pages (from-to)19911-19928
Number of pages18
JournalOncotarget
Volume9
Issue number28
DOIs
StatePublished - Apr 13 2018

Fingerprint

Fluorouracil
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Cadherins
Colonic Neoplasms
Glycogen Synthase Kinase 3
Catenins
Phosphatidylinositol 3-Kinases
Gene Silencing
Caspase 3
Phosphorylation
Apoptosis
Messenger RNA

Keywords

  • 5-Fluorouracil resistance
  • COX-2
  • E-cadherin
  • Over-activation of AKT
  • SNU-C5/5-FU

Cite this

Kim, E. J., Kang, G. J., Kang, J. I., Boo, H. J., Hyun, J. W., Koh, Y. S., ... Kang, H. K. (2018). Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells. Oncotarget, 9(28), 19911-19928. https://doi.org/10.18632/oncotarget.24952

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells. / Kim, Eun Ji; Kang, Gyeoung Jin; Kang, Jung Il; Boo, Hye Jin; Hyun, Jin Won; Koh, Young Sang; Chang, Weon Young; Kim, Young Ree; Kwon, Jung Mi; Maeng, Young Hee; Yoo, Eun Sook; Lee, Chang Hoon; Kang, Hee Kyoung.

In: Oncotarget, Vol. 9, No. 28, 13.04.2018, p. 19911-19928.

Research output: Contribution to journalArticle

Kim, EJ, Kang, GJ, Kang, JI, Boo, HJ, Hyun, JW, Koh, YS, Chang, WY, Kim, YR, Kwon, JM, Maeng, YH, Yoo, ES, Lee, CH & Kang, HK 2018, 'Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells', Oncotarget, vol. 9, no. 28, pp. 19911-19928. https://doi.org/10.18632/oncotarget.24952
Kim, Eun Ji ; Kang, Gyeoung Jin ; Kang, Jung Il ; Boo, Hye Jin ; Hyun, Jin Won ; Koh, Young Sang ; Chang, Weon Young ; Kim, Young Ree ; Kwon, Jung Mi ; Maeng, Young Hee ; Yoo, Eun Sook ; Lee, Chang Hoon ; Kang, Hee Kyoung. / Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells. In: Oncotarget. 2018 ; Vol. 9, No. 28. pp. 19911-19928.
@article{6bd10c39bcb84b60933a4eb14fcfdab1,
title = "Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells",
abstract = "Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho- GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5- FU cells. These data suggest that inhibition of AKT activation may overcome 5-FUresistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment.",
keywords = "5-Fluorouracil resistance, COX-2, E-cadherin, Over-activation of AKT, SNU-C5/5-FU",
author = "Kim, {Eun Ji} and Kang, {Gyeoung Jin} and Kang, {Jung Il} and Boo, {Hye Jin} and Hyun, {Jin Won} and Koh, {Young Sang} and Chang, {Weon Young} and Kim, {Young Ree} and Kwon, {Jung Mi} and Maeng, {Young Hee} and Yoo, {Eun Sook} and Lee, {Chang Hoon} and Kang, {Hee Kyoung}",
year = "2018",
month = "4",
day = "13",
doi = "10.18632/oncotarget.24952",
language = "English (US)",
volume = "9",
pages = "19911--19928",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

TY - JOUR

T1 - Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells

AU - Kim, Eun Ji

AU - Kang, Gyeoung Jin

AU - Kang, Jung Il

AU - Boo, Hye Jin

AU - Hyun, Jin Won

AU - Koh, Young Sang

AU - Chang, Weon Young

AU - Kim, Young Ree

AU - Kwon, Jung Mi

AU - Maeng, Young Hee

AU - Yoo, Eun Sook

AU - Lee, Chang Hoon

AU - Kang, Hee Kyoung

PY - 2018/4/13

Y1 - 2018/4/13

N2 - Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho- GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5- FU cells. These data suggest that inhibition of AKT activation may overcome 5-FUresistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment.

AB - Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho- GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5- FU cells. These data suggest that inhibition of AKT activation may overcome 5-FUresistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment.

KW - 5-Fluorouracil resistance

KW - COX-2

KW - E-cadherin

KW - Over-activation of AKT

KW - SNU-C5/5-FU

UR - http://www.scopus.com/inward/record.url?scp=85045343678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045343678&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24952

DO - 10.18632/oncotarget.24952

M3 - Article

C2 - 29731993

AN - SCOPUS:85045343678

VL - 9

SP - 19911

EP - 19928

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -